FDA delays decision on abuse deterrence data on Endo painkillerData could be used to fend off generic competition. Share XFDA delays decision on abuse deterrence data on Endo painkillerhttps://pharmaphorum.com/news/fda-delays-decision-on-key-abuse-deterrence-data-on-endo-painkiller/
AZ sells anaesthetics rights to AspenSouth African firm will pay $770 million. Share XAZ sells anaesthetics rights to Aspenhttps://pharmaphorum.com/news/az-sell-rights-anaesthetics-pharmacare/